A Cross-sectional Study on IBS Subtypes, Chinese Medicine Pattern and Host-gut Microbiota Metabolic Interactions
The Distribution of Irritable Bowel Syndrome (IBS) Subtypes, Chinese Medicine Pattern and Host-gut Microbiota Metabolic Interactions Associated With IBS Subtypes
1 other identifier
observational
504
1 country
1
Brief Summary
The investigators will conduct a cross-sectional study to discovery the distribution of IBS subtypes who would like to seek TCM treatment and their TCM patterns. At the same time, the investigators will also collect the serum, urine and stool samples of the participants to explore the host-gut microbiota metabolic interactions associated with IBS subtypes.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for all trials
Started Jul 2016
Shorter than P25 for all trials
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
June 30, 2016
CompletedFirst Posted
Study publicly available on registry
July 4, 2016
CompletedStudy Start
First participant enrolled
July 7, 2016
CompletedPrimary Completion
Last participant's last visit for primary outcome
January 16, 2017
CompletedStudy Completion
Last participant's last visit for all outcomes
January 30, 2017
CompletedAugust 16, 2017
August 1, 2017
6 months
June 30, 2016
August 14, 2017
Conditions
Outcome Measures
Primary Outcomes (1)
the Distribution of IBS Subtype and Their CM Pattern in Hong Kong Population.
one year
Secondary Outcomes (3)
the Host-gut Microbiota Metabolic Interactions Associated with IBS Subtypes
one year
the Relationship Between CM Pattern and Their Microbiota
one year
the relationship between CM pattern and metabolic profiling
one year
Eligibility Criteria
IBS Patients
You may qualify if:
- \) meet of diagnosis of IBS(ROME 4); 2) age of 18 to 65 years (inclusive); 3) IBS Symptom Severity Scale \[17\] (IBS-SSS) \> 75 points (a range of 0-500 points of VAS on five questions) at baseline and during the 2-week run-in period; 4) Normal colonic evaluation (colonoscopy or barium enema) within 5 years; 5) Written informed consent.
You may not qualify if:
- \) pregnancy or breast-feeding; 2) medical history of inflammatory bowel diseases, carbohydrate malabsorption, hormonal disorder, known allergies to food additives, and/or any other serious diseases; 3) Having suicidal ideas or attempts or aggressive behavior; 4) Use of medications known to influence gastrointestinal transit.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
School of Chinese Medicine, Hong Kong Baptist University
Hong Kong, Hong Kong, China
Biospecimen
Serum: The participants will be instructed to meet fasting for the blood sample collection and 15ml whole blood will be drawn from the participants. Stool: Fecal samples should be naturally excreted from subjects (500ml at least) and should be collected without mixing with urine, sanitizer and sewage. Urine: Mid-stream morning urine will be collected.
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Zhao-xiang Bian, PhD
Hong Kong Baptist University
Study Design
- Study Type
- observational
- Observational Model
- OTHER
- Time Perspective
- CROSS SECTIONAL
- Target Duration
- 7 Days
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Chair Professor
Study Record Dates
First Submitted
June 30, 2016
First Posted
July 4, 2016
Study Start
July 7, 2016
Primary Completion
January 16, 2017
Study Completion
January 30, 2017
Last Updated
August 16, 2017
Record last verified: 2017-08